Skip to main content

Tourette Syndrome and cannabis in Alabama

The state explicitly lists this condition under its medical cannabis program. A certifying physician can pursue state registration for a patient with this diagnosis under the program rules.

Listed qualifying condition
✓ Yes
LEGAL
Physician-certified med…
POSSESSION
$65/yr
STATE FEE
7–30 d
TIMELINE
Listed qualifying condition. The state explicitly lists this condition under its medical cannabis program. A certifying physician can pursue state registration for a patient with this diagnosis under the program rules.

Alabama statute and program

The Alabama Medical Cannabis Program (Darren Wesley 'Ato' Hall Compassion Act) is the operating authority for Alabama patient certification. The authoritative legal text is: Alabama Compassion Act (SB 46 of 2021).

What the evidence says about cannabis and Tourette Syndrome

Tourette syndrome (TS) is a neurodevelopmental disorder characterized by multiple motor tics and one or more vocal tics, with onset typically in childhood. Tic severity varies widely; many patients experience meaningful improvement by adulthood, but a significant minority continue to have functionally disabling tics that respond poorly to first-line behavioral and pharmacologic therapies.

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Tourette Syndrome page.

How to qualify in Alabama

The Alabama Medical Cannabis Program (Darren Wesley 'Ato' Hall Compassion Act) requires the following registration steps for a Tourette Syndrome patient (or any qualifying diagnosis):

  1. See an Alabama-licensed certifying physician. Under the Darren Wesley "Ato" Hall Compassion Act (Alabama Act 2021-450), only physicians who have completed the four-hour Alabama Medical Cannabis Commission (AMCC) certification course and registered with the AMCC may certify patients. The physician evaluates the patient for one of the enumerated qualifying conditions (autism, cancer-related cachexia or chronic pain, Crohn’s, depression, epilepsy, HIV/AIDS, panic disorder, Parkinson’s, PTSD, sickle-cell, intractable pain, terminal illness, and others under §20-2A-3).
  2. Register through the AMCC patient portal. After certification, the patient creates an account in the AMCC patient registry using a current Alabama driver license or state ID. The physician’s certification is linked electronically to the patient’s record. Caregivers (required for minor patients) register separately and pass a state and federal background check.
  3. Pay the $65 state registration fee. The annual AMCC patient registration fee is $65 (caregiver registration is also $65). Once paid, the patient receives a digital medical cannabis card. The program does not yet have brick-and-mortar dispensaries open as of the program’s phased launch — operating dispensary licenses were issued in 2024 with retail expected to begin in 2025.
  4. Purchase from an AMCC-licensed dispensary. With the digital card and Alabama ID, patients may purchase Alabama-permitted forms (tablets, capsules, tinctures, gels, oils, gummies, lozenges, suppositories, topical patches, transdermal patches, nebulizers, and liquids or oils for use in an inhaler — no smokable flower, edibles intended to look like candy, or vaping products under §20-2A-3(15)). Adult-use cannabis remains illegal in Alabama.
State registration fee
$65
Physician visit (typical)
$200–$400
Certification to card
7–30 days
Out-of-state patients
Not eligible
Minors
Eligible with caregiver

For full Alabama registration steps, fees, and reciprocity rules, see the Alabama cannabis-laws page.

ICD-10 code

A certifying physician documenting Tourette Syndrome for the Alabama medical cannabis program will typically record ICD-10 F95.2 or SNOMED-CT 5158005 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does Alabama list Tourette Syndrome as a qualifying condition for medical cannabis?

Yes. Alabama explicitly lists Tourette Syndrome as a qualifying condition under Alabama Medical Cannabis Program (Darren Wesley 'Ato' Hall Compassion Act). A patient with a documented Tourette Syndrome diagnosis can pursue state-program certification with a physician registered in the state. The qualifying-condition list is set by state statute or regulation and may change. Inclusion on the list does not guarantee certification — a physician still has to evaluate the patient and decide that medical cannabis is appropriate for that specific case under Alabama rules.

How do I get a Alabama medical marijuana card for Tourette Syndrome?

Step one is finding a physician licensed in Alabama who is registered with Alabama Medical Cannabis Program (Darren Wesley 'Ato' Hall Compassion Act) and willing to evaluate Tourette Syndrome cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Alabama does not honor out-of-state cards, so the certification process has to originate inside the state. Verify the patient minimum age with the state program before applying. Confirm the current process with the state regulator before applying, because the rules change.

What does the evidence say about cannabis for Tourette Syndrome?

For Tourette Syndrome, evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Tourette Syndrome lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Tourette Syndrome should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Tourette Syndrome and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Tourette Syndrome; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. Alabama Compassion Act (SB 46 of 2021)accessed May 16, 2026
  2. Alabama Medical Cannabis Commissionaccessed May 16, 2026
  3. Wikipedia: Cannabis in Alabamaaccessed May 16, 2026
  4. Ala. Code §13A-12-214: Unlawful possession of marijuana (penalty schedule)accessed May 17, 2026
  5. Alabama SB 46 (2021): Darren Wesley 'Ato' Hall Compassion Actaccessed May 17, 2026
  6. Alabama Department of Agriculture & Industries: Industrial Hemp Programaccessed May 17, 2026
  7. Alabama Legislature bill trackeraccessed May 17, 2026
  8. NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 15, 2026

    “Limited evidence that THC capsules are effective for the treatment of Tourette syndrome.”

  9. Tourette Association of Americaaccessed May 15, 2026